Abstract-Observational studies have shown inconsistent results for the association between blood pressure and cancer risk. We investigated the association in 7 cohorts from Norway, Austria, and Sweden. In total, 577799 adults with a mean age of 44 years were followed for, on average, 12 years. Incident cancers were 22184 in men and 14744 in women, and cancer deaths were 8724 and 4525, respectively. Cox regression was used to calculate hazard ratios of cancer per 10-mmHg increments of midblood pressure, which corresponded with 0.7 SDs and, for example, an increment of systolic/diastolic blood pressure of 130/80 to 142/88 mmHg. All of the models used age as the time scale and were adjusted for possible confounders, including body mass index and smoking status. In men, midblood pressure was positively related to total incident cancer (hazard ratio per 10 mmHg increment: 1.07 [95% CI: 1.04 -1.09]) and to cancer of the oropharynx, colon, rectum, lung, bladder, kidney, malignant melanoma, and nonmelanoma skin cancer. In women, midblood pressure was not related to total incident cancer but was positively related to cancer of the liver, pancreas, cervix, uterine corpus, and malignant melanoma. A positive association was also found for cancer mortality, with HRs per 10-mmHg increment of 1.12 (95% CI: 1.08 -1.15) for men and 1.06 (95% CI: 1.02-1.11) for women. These results suggest a small increased cancer risk overall in men with elevated blood pressure level and a higher risk for cancer death in men and women. (Hypertension. 2012;59:00-00.) • Online Data Supplement Key Words: blood pressure Ⅲ neoplasms Ⅲ prospective studies Ⅲ cohort studies Ⅲ Cohort of Norway H ypertension accounts for Ϸ5% of the current global disease burden because of increasing longevity and prevalence of contributing factors, such as obesity, physical inactivity, and an unhealthy diet.
H ypertension accounts for Ϸ5% of the current global disease burden because of increasing longevity and prevalence of contributing factors, such as obesity, physical inactivity, and an unhealthy diet. 1 Increasing age and metabolic aberrations related to obesity, for example, hyperglycemia and hypercholesterolemia, have been linked to increased risk of cancer, 2, 3 and several lines of evidence also suggest a link between hypertension and cancer risk. [4] [5] [6] [7] [8] However, there are only a few observational studies of the association between blood pressure (BP) and cancer incidence and mortality, which show inconsistent findings. 9, 10 In a meta-analysis based on 10 longitudinal studies of in total 47 119 participants, hypertension was related to a 23% increased risk of cancer mortality, 9 and in another study including 17 498 participants, BP was inversely associated with mortality from leukemia and pancreatic cancer but positively associated with mortality attributed to liver and rectal cancer. 11 The association between hypertension and incident cancer has also been found to differ by cancer site. 10 These studies were hampered by small study size and/or lack of information on potential confounders, such as smoking habits and obesity. Moreover, assessment of BP on a single occasion entails a substantial random error attributed to measurement error and within-person variation of BP levels. 12, 13 Such inaccuracy of exposure assessment dilutes the association with outcome, that is, regression dilution bias. 12, 14, 15 Risk estimates can be corrected for this random error in exposure classification by using data from multiple examinations. 16 To our knowledge, no study to date on BP and overall cancer has applied such correction.
We aimed to overcome these limitations by studying the association between BP and cancer incidence and mortality in a large study of 7 European prospective cohorts in which we corrected for random error in BP levels.
Methods

Study Population
The Metabolic Syndrome and Cancer Project includes 7 populationbased cohorts from Norway, Austria, and Sweden. The project has been described in detail previously. 17 Briefly, the aim of the Metabolic Syndrome and Cancer Project is to investigate the relation between metabolic factors and cancer risk. Participants in Metabolic Syndrome and Cancer Project cohorts took part in health examination(s) between 1972 and 2005, from which in the current study we used information on weight, height, BP, and smoking status. In all of the cohorts, weight was measured in light indoor clothing and height without shoes. Different methods were used to assess BP. Resting time before BP measurement varied from 2 to 10 minutes, body position was sitting or supine, and the equipment was a mercury sphygmomanometer or an automatic device. 17 Smoking status was obtained from a questionnaire in all of the cohorts, except in the Austrian cohort, where the examining physician entered the information. For the present study, the same data set was used as in our previous studies on the metabolic syndrome and risk of different cancers, 17 except that 901 participants with data missing on BP were not included in the present study. We included all 577 799 participants with no previous cancer diagnosis at the time of baseline health examination who had a body mass index (BMI) between 15 and 60 kg/m 2 , a systolic BP of Ն75 mm Hg, and a diastolic BP of Ն40 mm Hg. The study project was approved by research ethical committees in Norway, Austria, and Sweden.
To obtain information on cancer diagnoses, cause of death, and migration (migration only for Sweden and Norway), each cohort was linked to their national Cancer Register, Cause of Death Register, and Population Register. Incident and fatal cancers were classified according to the International Classification of Diseases, seventh revision, and grouped into cancer sites as in the Eurostat European shortlist for cause of death. 18 Hazard ratios (HRs) for cancer incidence and mortality at specific sites are presented separately for men and women but for men and women combined if the number of cases in each group was Յ50.
Statistical Analysis
Rates, HRs, and absolute risks of cancer by BP level were calculated with follow-up starting 1 year after the baseline examination. Participants were followed until the date of event, that is, cancer diagnosis or cancer death, or until the date of death from any cause, emigration, or end of follow-up, whichever occurred first. Rates were directly age standardized in 5-year categories, using the European standard population as the reference. 19 We used Cox proportional hazards regression to calculate HRs for cancer by BP level. Attained age was used as the time variable, and all of the estimates were stratified by subcohort, sex, and 6 categories of birth year and were adjusted for age at measurement (continuous), BMI (categories: Ͻ22.5, 22.5-24.9, 25.0 -27.4, 27.5-29.9, 30.0 -32.4, and Ն32.5 kg/m 2 ), and smoking status (categories: never smoker, ex-smoker, current smoker, and unknown). HRs for cancer overall were calculated by levels of systolic BP, diastolic BP, and mid-BP ([systolic BP ϩ diastolic BP]/2), and the latter was also assessed in relation to cancer risk at sites. Mid-BP was primarily used because it is a strong predictor of cardiovascular mortality. 20 This measure with equal weights for systolic and diastolic BPs can be considered the most reasonable choice in the absence of knowledge about BP predictors in relation to cancer. We estimated HRs for BP in quintiles and deciles, for which cut points were calculated within each subcohort and sex. P for trend over quintiles refers to the P value for the Wald test of a linear risk estimate, assigning participants the mean sexand cohort-specific BP level within the corresponding quantile group. HR was also assessed for BP as a continuous variable per 10-mm Hg increment, which, in our cohort for mid-BP corresponded with a 0.7 SD increment and, for example, an increment of systolic BP/diastolic BP of Interaction between mid-BP and subcohort and categories of BMI, respectively, were checked by calculating cohort and BMI-specific HRs and by performing likelihood ratio tests comparing the linear model with a model that additionally included a product term of mid-BP and cohort or BMI in categories. All of the HRs were corrected for random error in BP measurement, [12] [13] [14] [15] which is described in detail in Supplemental Methods, available in the online-only Data Supplement.
Absolute risk of cancer between age 50 and 70 years was calculated as described by Gail et al. 21 In these calculations, risk of cancer and of dying from other causes than cancer was derived from the cohort for ages 50 to 60 years and 60 to 70 years, respectively.
Statistical analyses were performed in Stata 10.0 and R 2.7.2 (R used for regression dilution ratio calculation). Two-sided P values Ͻ0.05 and HRs with 95% CIs not overlapping unity were considered statistically significant.
Results
Baseline Characteristics
Mean age at baseline was 43.9 years for men and 44.1 years for women (Table 1 ). Approximately 55% of men (range: 41% to 64% in cohorts) and 41% of women (range: 35% to 49%) were overweight or obese (BMI Ն25 kg/m 2 ), and 38% of men (range: 28% to 49%) and 26% of women (range: 12% to 34%) had hypertension (systolic/diastolic BP Ն140/90 mm Hg). A total of 22 184 men and 14 744 women developed cancer during follow-up, and 8724 men and 4525 women died of cancer.
Linearity and Heterogeneity Between Cohorts
Analyses of mid-BP in deciles showed linear associations with HRs of cancer incidence and mortality in men ( Figure 1 ) and women (Figure 2) , which supports the use of linear models for calculation of cancer risk overall. In linear models of mid-BP, we found some evidence for interaction between mid-BP and different cohorts in relation to cancer risk. However, statistical significance was only obtained for cancer mortality (Pϭ0.04 for men and 0.02 for women) and not for incident cancer. Moreover, the cohort showing the weakest and strongest association, respectively, was not consistent between men and women or between cancer incidence and mortality, suggesting a random interaction.
BP and Incident Cancer
HRs for BP and incident cancer risk is shown in Table 2 for total cancer and cancers with significant associations in men or women, and in Table S1 (please see the online-only Data Supplement) for all of the cancers investigated. In both men and women, systolic and diastolic BPs showed very similar associations with cancer risk overall. For cancer at separate sites, significant linear associations in analysis per 10-mm Hg increment of mid-BP were found among men for cancers of the oropharynx, colon, rectum, lung, bladder, kidney, and malignant melanoma and nonmelanoma skin cancer. In addition, the highest quintile of mid-BP was significantly related to the risk of pancreas cancer. Among women, mid-BP was positively associated with incident cancer of the liver, pancreas, cervix and corpus uteri, and malignant melanoma. A positive association was also found for esophagus cancer in men and women combined.
We also estimated the risk of incident cancer for hypertension as defined by the World Health Organization. For men, HR for a systolic BP Ն140 mm Hg was 1.17 (95% CI: 1.10 -1.23), which for a 50-year old man corresponded with an absolute 20-year risk of cancer increasing from 13.7% for normal systolic BP to 15.6% for hypertension. The HR for diastolic BP Ն90 mm Hg was 1.15 (95% CI: 1.09 -1.22), and the corresponding absolute risks were 14.1% and 15.9% for normal and hypertensive diastolic BP, respectively. In women, HRs for hypertension versus normal levels were nonsignificant, at 1.06 (95% CI: 0.99 -1.14) for systolic BP and 1.08 (95% CI: 0.99 -1.17) for diastolic BP.
BP and Cancer Mortality
A positive association by quintiles and 10-mm Hg increments of BP was found for cancer mortality among men and women (Table 3 for significant cancers and Table S2 for all of the cancers investigated). In men, the HR for a 10-mm Hg increment was 1.12 (95% CI: 1.08 -1.15), and for the fifth versus first quintile it was 1.49 (95% CI: 1.31-1.71). In women, these HRs were 1.06 (95% CI: 1.02-1.11) and 1.24 (95% CI: 1.02-1.50), respectively.
For death from cancer of specific sites among men, a significant positive association per 10-mmHg increment was shown for cancers of the oropharynx, rectum, pancreas, lung, prostate, bladder, and kidney. Positive associations per 10-mmHg increments in women were found for cancer of the pancreas, breast, corpus uteri, and malignant melanoma, and there was an inverse association with risk of ovarian cancer. A positive association was found for esophagus cancer in men and women combined.
When using the World Health Organization definition of hypertension, we found a HR of 1.30 (95% CI: 1.19 -1.42) for Hazard ratio
Figure 2.
Hazard ratio (95% confidence interval) of cancer incidence (e) and cancer mortality () by midblood pressure in deciles for women. Hazard ratios for decile categories are plotted on the x axis at the mean midblood pressure level for each decile category.
a systolic BP Ն140 mm Hg in men. This corresponded with an absolute 20-year risk of cancer death in a 50-year old man of 5.5% for normal systolic BP and 7.0% for high systolic BP. The HR for high diastolic BP (Ն90 mm Hg) was 1.17 (95% CI: 1.07-1.29), and absolute risks were 5.7% and 6.6%, respectively. Among women, HRs were 1.10 (95% CI: 0.97-1.26) for high systolic BP and 1.17 (95% CI: 1.02-1.34) for high diastolic BP. The absolute 20-year risk of cancer death in 50-year-old women was 4.2% for normal diastolic BP and 4.7% for high diastolic BP.
Robustness Analyses
To assess the possibility of reverse causation, we recalculated HRs after exclusion of the first 5 years of follow-up, but risk estimates for cancer incidence and mortality remained the same (Table S3) . We also investigated whether associations ʈData are per 100 000 person-y, age-standardized to the European standard population. ¶Data include other cancer than the separately presented sites (see Table S1 for complete list).
for mid-BP and cancer differed by follow-up period. Approximately 80% of cases were diagnosed between 1990 and 2004, with the median around the beginning of year 2000. There were no essential differences in associations for the time periods before versus after January 1, 2000 (Table S4 ).
BP and Cancer in Categories of BMI
BMI modified the association between mid-BP and cancer in men (Pϭ0.003 for cancer incidence and 0.002 for cancer mortality; Figure 3 ). In men with a BMI Ͻ22.5 kg/m 2 , HR of incident cancer per 10-mm Hg increment was 1.11 (95% CI: 1.05-1.17), and it was 1.22 (95% CI: 1.13-1.31) for cancer mortality. These associations decreased by increasing BMI category, and no associations were shown in obese men (BMI Ն30 kg/m 2 ). In women, BP was more strongly associated with cancer mortality for lower BMI categories, but no significant interaction between BMI categories and mid-BP was shown for cancer incidence (Pϭ1.0) or cancer mortality (Pϭ0.05; Figure 4) .
Discussion
This large prospective cohort study showed that elevated BP was statistically significantly associated with incident cancer in men and with cancer mortality in men and women, as well as with several specific cancers. Cancer risk increased linearly with increasing BP levels, and for both cancer incidence and mortality the association was stronger for men than for women. Among men, the absolute 20-year risk of cancer incidence or mortality at age 50 years was 1% to 2% points higher with hypertensive systolic or diastolic BPs compared with men with normal BP.
Strengths of our study include the large sample size from 7 European population-based cohorts with virtually complete capture of cancer cases, the use of incident cancer as well as cancer mortality as end points, and the correction of risk estimates for intraindividual variation of BP levels based on a large number of repeated measurements. [22] [23] [24] In all of the cohorts, data were available for BMI and smoking status, and these factors were used as adjustment in ʈData are per 100 000 person-y, age-standardized to the European standard population.
analyses. Limitations of our study include the lack of data on covariates, such as the use of antihypertensive medication, which may have influenced risk estimates. To date, however, the association between antihypertensive treatment and cancer risk is unknown. 25 Hypertension has been established as a risk marker in several observational studies of renal cell carcinoma. [26] [27] [28] A recent meta-analysis based on 18 studies found a 1.6-fold increase in the risk of renal cell carcinoma in participants with hypertension. 27 For other cancer sites, findings have been less consistent. For instance, endometrial cancer was not associated with hypertension in a US case-control study including 469 endometrial cancer cases, 29 but, in contrast, a 3-fold increased risk was observed for women with a history of hypertension or diabetes mellitus in a European hospital-based casecontrol study including 285 cases. 30 Inconsistent associations have also been found for cancer of the colon, breast, lung, and prostate. 8, [31] [32] [33] [34] A link between BP and cancer, as found in our study, could speculatively be mediated via proliferative abnormalities in vascular smooth muscle cells. 35 However, BP might be a proxy for another cancer risk factor, or the association between BP and cancer risk may be confounded by factors such as central obesity, which we might not have accurately adjusted for by the use of BMI.
Our study, which, to our knowledge, is the largest and the first to take into account random error in measurements, showed that the association between hypertension and cancer incidence or cancer mortality was stronger for men than for women. In contrast, the second largest study (nϭ20 529) only found a statistically significant association between hypertension and cancer of the endometrium and kidney. 28 However, in that study, the HR for pancreatic cancer was higher for hypertensive women than for hypertensive men, in accordance with our findings for 10-mm Hg increments. Moreover, they found that the risk of lung cancer was reduced for hypertensive participants. Differences in findings between these studies may be attributed to our larger sample size, slightly older population, or lack of information on antihypertensive treatment.
The association for BP with cancer mortality overall was stronger than for incident cancer. The explanation for this difference may vary between cancer types. Speculatively, for some tumors, high BP and related factors are more important for progression than for tumor initiation. Alternatively, participants with high BP may be diagnosed with cancer at a later stage, for example, because of different healthcare-seeking behavior, or the results may be caused by inconsistencies in classification of cancer diagnosis versus cause of death. 36, 37 Moreover, we found that the association between BP and cancer differed by BMI level in men but not in women. Speculatively, this difference between men and women may be related to an interplay between sex hormones and BP in relation to cancer. More studies are needed to investigate a potential role for high BP in tumor initiation and progression and whether BP interacts with other metabolic and carcinogenic factors on the risk of cancer.
Perspectives
In the general population of cohorts from 3 European countries, BP was linearly, positively related to incident cancer in men and cancer mortality in men and women. The relative and absolute risk estimates were modest, but from a public health perspective these results are important because hypertension is highly prevalent in many Western countries. No evidence for reverse causation was found for the association. However, the mechanisms behind elevated BP and subsequent increased cancer risk must be investigated with more detailed information on potential confounders, cancer phenotypes, and BP-related characteristics. In particular, antihypertensive medication needs additional attention, because it is a common treatment for hypertension and may, independent of BP level, influence cancer risk. The most important message from this study is that high BP not only increases the risk of cardiovascular mortality 20 but also appears to increase the risk of cancer. 
ONLINE SUPPLEMENT Blood Pressure and Risk of Cancer
SUPPLEMENTAL METHODS
Calculation of random error in BP measurement
HRs were corrected for random error in BP measurement (12, 13) . These calculations were based on data from 133 820 participants with two or more observations with the same fasting time before measurements, in total 406 364 observations. The mean time between baseline and repeated measurements was 6.9 years (SD: 3.9). We used a linear mixed effects model, similar to that described by Wood et al. (15) , for calculation of regression dilution ratio (RDR). The baseline measurement was used as independent variable and the repeated measurement as dependent variable. Age at baseline, fasting time, smoking status, sex, BMI, birth year, and time from baseline, were included as fixed effects in the model, and cohort was included as random effect. The estimated RDR decreased with time between baseline and repeated measurement so a product term for time and BP was also included. In order to obtain the "usual value" of BP, RDR was predicted for the time point at six years after baseline measurement, i.e. half the follow-up time (14) . The calculated RDRs were for mid-BP, 0.53 in men, 0.56 in women, and 0.54 for men and women combined; systolic BP, 0.51 in men, and 0.54 in women, diastolic BP, 0.48 in men, and 0.51 in women. HRs were corrected for RDR by exp(log(HR)/RDR). (18) . ‡Hazard ratios are presented separately for men and women if the number of cases in each group was more than 50, and combined if the number of cases in each group was less than or equal to 50 and if the total number of cases was more than 80.
§Hazard ratios per unit increment excluding outliers (<0.05% of participants): mid-BP>180 mmHg, SBP>230 mmHg, and DBP>130 mmHg. Number of cases corresponds to quintile analyses which included all participants. ||Per 100 000 person-years, age-standardized to the European standard population. ¶Other cancer than the separately presented sites. HR indicates hazard ratio; CI, confidence interval; ref, referent group. *Hazard ratio by blood pressure estimated in Cox models with attained age as time scale, stratified by cohort, sex, and birth year, and adjusted for baseline age, body mass index, and smoking status. HRs are corrected for regression dilution ratio (RDR); conversion into uncorrected HR = exp(log(HR)*RDR). RDR mid-BP: men, 0.53; women, 0.56; all, 0.54. †Hazard ratios per unit increment excluding outliers with mid-BP>180 mmHg (<0.05% of participants). Number of cases corresponds to quintile analyses which included all participants. HR indicates hazard ratio; CI, confidence interval; ref, referent group. *Hazard ratio by blood pressure estimated in Cox models with attained age as time scale, stratified by cohort, sex, and birth year, and adjusted for baseline age, body mass index, and smoking status. HRs are corrected for regression dilution ratio (RDR); conversion into uncorrected HR = exp(log(HR)*RDR). RDR mid-BP: men, 0.53; women, 0.56; all, 0.54. †Numbers do not sum up to the total number of cancers because 17 incident cancers and three cancer deaths occurred on January 1, 2000. These events are thus not included.
‡Hazard ratios per unit increment excluding outliers with mid-BP>180 mmHg (<0.05% of participants). Number of cases corresponds to quintile analyses which included all participants.
